ESTRO 2024 - Abstract Book

S1739

Clinical - Lung

ESTRO 2024

Conclusion:

Dose escalation up to a mean dose of 95 Gy in 33 fx was achieved for the PET based dose escalation volumes in the primary tumor, and adherence to the protocol constraints was excellent. The high dosimetric compliance provides a solid foundation for the primary endpoint analysis which is scheduled for March 2024.

Keywords: NSCLC, dose escalation

2466

Digital Poster

Characteristics and outcomes of lung cancer patients managed through a multidisciplinary setting

Alexandra Ferrera 1 , Claire Barker 2 , Jennifer King 2 , Felice Granato 3 , Siobhan Keegan 3 , Rebecca Stephens 3 , Cassandra Ng 4 , Matthew Evison 3 , Kathryn Banfill 2 1 The Christie NHS Foundation Trust, Clinical oncology, Manchester, United Kingdom. 2 The Christie NHS Foundation Trust, Lung oncology, Manchester, United Kingdom. 3 Manchester University NHS Foundation Trust, Department of thoracic oncology, Manchester, United Kingdom. 4 Manchester University NHS Foundation Trust, Geriatric medicine, Manchester, United Kingdom

Purpose/Objective:

The One-Stop Lung Cancer Clinic was introduced in June 2022 at our centre to allow patients with radically treatable lung cancers to meet different treatment specialists on the same day including oncologists, surgeons, anaesthetists, geriatricians, and nurse specialists. The introduction of the clinic aimed to reduce hospital visits, improve the patient experience, and reduce time to starting treatment. We aimed to evaluate the characteristics and outcomes of patients attending the One-Stop clinic in its first 12 months.

Material/Methods:

241 patients with stage I-III lung cancer, who attended the One-Stop Lung Clinic between 17/06/2022 and 13/06/2023 had their data reviewed up to the cut-off date of 16/09/2023. Data on treatment outcome, age, stage, performance status (PS), clinical frailty scale (CFS), presence of interstitial lung disease (ILD), smoking status, predicted post-operative FEV1 (ppo-FEV1), recurrence and death were collected. We omitted patients attending the clinic with metastatic or recurrent disease. Patients were categorised as receiving surgery, radiotherapy or “other”, which included patients who went on to have best supportive care, active surveillance, systemic therapy, radiofrequency ablation or declined treatment. SABR regimens were 48-60 Gray (Gy) in 3-8 fractions (#). Concurrent regimens were 60Gy in 30# given with chemotherapy. Conventional regimens were 50-60 Gy in 15-20#, with or without sequential chemotherapy. Palliative doses were 30Gy in 10#.